Bank of Montreal Can Has $528,000 Stock Holdings in Neogen Corporation $NEOG

Bank of Montreal Can increased its stake in Neogen Corporation (NASDAQ:NEOG) by 171.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 110,406 shares of the company’s stock after acquiring an additional 69,703 shares during the quarter. Bank of Montreal Can owned about 0.05% of Neogen worth $528,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Avanza Fonder AB raised its holdings in Neogen by 17.9% during the 2nd quarter. Avanza Fonder AB now owns 16,435 shares of the company’s stock worth $79,000 after purchasing an additional 2,499 shares during the last quarter. Gabelli Funds LLC raised its stake in Neogen by 9.5% during the first quarter. Gabelli Funds LLC now owns 63,500 shares of the company’s stock worth $551,000 after buying an additional 5,500 shares during the last quarter. New York State Teachers Retirement System lifted its holdings in Neogen by 4.3% in the second quarter. New York State Teachers Retirement System now owns 134,066 shares of the company’s stock valued at $641,000 after buying an additional 5,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Neogen by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 129,813 shares of the company’s stock valued at $1,125,000 after buying an additional 5,638 shares during the period. Finally, Bank Pictet & Cie Europe AG boosted its position in Neogen by 6.4% during the second quarter. Bank Pictet & Cie Europe AG now owns 99,025 shares of the company’s stock valued at $473,000 after acquiring an additional 5,975 shares during the last quarter. 96.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NEOG has been the subject of several research analyst reports. Wall Street Zen lowered Neogen from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. CJS Securities began coverage on Neogen in a research note on Monday, September 29th. They issued a “market perform” rating and a $10.00 price target on the stock. Zacks Research raised shares of Neogen from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 20th. William Blair downgraded shares of Neogen from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 29th. Finally, Piper Sandler set a $6.50 price target on shares of Neogen and gave the stock a “neutral” rating in a report on Thursday, October 16th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.83.

Neogen Trading Up 0.5%

NASDAQ NEOG opened at $6.42 on Tuesday. The company has a current ratio of 3.58, a quick ratio of 2.26 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $5.93 and a 200 day simple moving average of $5.62. Neogen Corporation has a 12 month low of $3.87 and a 12 month high of $15.73. The firm has a market capitalization of $1.40 billion, a P/E ratio of -1.34 and a beta of 1.90.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.